Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-24 (MK-6018) Monotherapy and Combination with Pembrolizumab in Advanced Malignancies
NCT02346955Phase 1Terminated
- Sponsor
- FameWave
- Start
- Feb 2015
- Primary completion
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label trial of cm-24 in non-small cell lung carcinoma (NSCLC), melanoma, bladder cancer and 3 more (9 cohorts), sponsored by FameWave. Primary endpoints: Number of participants with Adverse Events (AEs) up to 123 weeks, Number of participants discontinuing study drug due to AEs up to 105 weeks and 1 more. Started Feb 2015; status: terminated.
02
Drugs
cm-24
03
Conditions
non-small cell lung carcinoma (NSCLC)melanomabladder cancercolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02346955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346955.